On May 28, 2024, Asahi Kasei Corporation announced a public offer to acquire all shares and American Depositary Shares (ADSs) in Calliditas Therapeutics AB, a Swedish company. By August 30, 2024, the offer had been accepted by stakeholders holding 83.37% of Calliditas’ shares and ADSs. Asahi Kasei plans to settle the tendered shares by September 9, 2024, and has decided to launch a subsequent offering period until September 13, 2024, for remaining stakeholders. Post-settlement, Asahi Kasei will control 93.30% of the shares. The company intends to convert its ADSs into shares, start a compulsory buy-out for remaining shares, and delist Calliditas from Nasdaq Stockholm and Nasdaq Global Select Market.
Biotechnology, Pharmaceuticals, Investment Management,Sweden, United States, Japan
https://sofinnovapartners.com/news/asahi-kasei-completes-the-recommended-public-cash-offer-and-becomes-the-owner-of-93-30-per-cent-of-all-shares-in-calliditas